SCHEMBL23924232

SCHEMBL23924232

Cc1ccc(OC2CC(NC(=O)O)C2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 8/20 0.48
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
FFAR4 Q5NUL3 1/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NPC1 O15118 1/20 0.38
CYP1A2 P05177 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
FAAH O00519 1/20 0.38
NAAA Q02083 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924231 1.00 EPHX2 (0.48) EPHX2MEN1KMT2AFFAR4LMNA
SCHEMBL16468050 0.85 EPHX2 (0.49) EPHX2MEN1KMT2ALMNAALDH1A1
SCHEMBL9279056 0.85 EPHX2 (0.49) EPHX2MEN1KMT2AFFAR4NPC1
SCHEMBL23924019 0.85 EPHX2 (0.54) EPHX2LMNAFAAH
SCHEMBL9279055 0.85 EPHX2 (0.49) EPHX2MEN1KMT2AFFAR4NPC1
SCHEMBL16468048 0.85 EPHX2 (0.49) EPHX2MEN1KMT2ALMNAALDH1A1
SCHEMBL23924020 0.85 EPHX2 (0.54) EPHX2LMNAFAAH
SCHEMBL26933138 0.85 OPRM1 (0.41) EPHX2MEN1KMT2AALDH1A1CYP1A2
SCHEMBL26933143 0.85 OPRM1 (0.41) EPHX2MEN1KMT2AALDH1A1CYP1A2
SCHEMBL26933175 0.83 FFAR4 (0.41) EPHX2FFAR4FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 EPHX2 2416/4885MEN1 4081/4885KMT2A 1332/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 EPHX2 2416/4885MEN1 4081/4885KMT2A 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.